drugset / Trial / NCT06273943
Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate if offering long-acting injectable cabotegravir (CAB-LA) as an additional HIV prevention choice among oral PrEP-experienced men who have sex with men (MSM) in France can significantly increase the sustained PrEP use over time and the PrEP coverage of at-risk sexual risk behaviors.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2025-10-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabotegravir | Small molecule | 600 mg | Oral |
| Comparator | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |
| Comparator | emtricitabine | Other / unclassified | 200 mg | Oral |
Indications
No indication recorded.